Overall, these results support a consistent synergistic effect of EGFR and JAK/STAT3 inhibition on ovarian cancer cell growth and survival both in vitro and in vivo and a potential role for multiple survival pathways in this effect. Here, EGFR is linked to ovarian carcinoma.